Breast Cancer Clinical Trial
Official title:
Stress Reduction For Breast Cancer in Women 55 Years of Age or Older: Enhancing Quality of Life and Survival
RATIONALE: Transcendental meditation may be an effective way to decrease the amount of
stress in older women with breast cancer. It is not yet known if transcendental meditation
is more effective than basic breast cancer education in improving quality of life.
PURPOSE: This randomized clinical trialstudies stress reduction in improvingquality of life
in older women with stage II, stage III, or stage IV breast cancer.
OBJECTIVES:
- Compare the effects of active stress reduction with transcendental meditation vs basic
breast cancer education on quality of life and survival time in older women with stage
II, III, or IV breast cancer.
- Determine behavioral mechanisms that may mediate the effects of stress reduction on
survival in these patients.
- Determine baseline variables that contribute to predicting survival time in these
patients.
OUTLINE: This is a randomized, single blind (to medical staff), multicenter study. Patients
are stratified according to age and participation in support groups. Patients with stage IV
disease are also stratified according to type of metastases (visceral vs non-visceral) and
timing of metastases (first diagnosis vs recurrence). Patients are randomized to 1 of 2
treatment arms.
- Arm I: Patients receive usual medical care and instruction on stress reduction using
transcendental meditation (TM), which involves a standard 7-step course. Patients
attend training for approximately 1-1.5 hours per session for a total of 6 sessions
over 1 week, while receiving usual medical care. Patients then practice TM twice a day
for 20 minutes. Patients attend group meetings for approximately 90 minutes once or
twice monthly for 6 months to ensure proper technique and understanding.
- Arm II: Patients receive usual medical care and basic literature on breast cancer.
Quality of life is assessed at baseline and then every 6 months for up to 3 years.
Patients are followed monthly for up to 2.5 years.
PROJECTED ACCRUAL: Approximately 166 patients (83 per treatment arm) will be accrued for
this study within 6 months.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |